Alpha Crest Capital Management LLC Natera, Inc. Transaction History

Alpha Crest Capital Management LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$36.93 - $56.68 $252,675 - $387,804	6,842 New	6,842 $300,000
Q1 2022 May 12, 2022	SELL	$30.32 - $91.33 $291,617 - $878,411	-9,618 Closed	0 $0
Q4 2021 Feb 09, 2022	BUY	$86.26 - $119.0 $459,852 - $634,389	5,331 Added 124.35%	9,618 $898,000
Q3 2021 Nov 10, 2021	BUY	$100.17 - $126.36 $429,428 - $541,705	4,287 New	4,287 $478,000
Q2 2021 Aug 12, 2021	SELL	$86.05 - $119.72 $195,161 - $271,524	-2,268 Closed	0 $0
Q1 2021 May 13, 2021	SELL	$91.47 - $124.36 $94,397 - $128,339	-1,032 Reduced 31.27%	2,268 $230,000
Q4 2020 Feb 12, 2021	BUY	$66.66 - $111.74 $219,978 - $368,742	3,300 New	3,300 $328,000
Q2 2020 Aug 12, 2020	SELL	$26.36 - $49.86 $590,464 - $1.12 Million	-22,400 Closed	0 $0
Q1 2020 May 13, 2020	BUY	$17.27 - $40.17 $25,905 - $60,255	1,500 Added 7.18%	22,400 $669,000
Q4 2019 Feb 12, 2020	SELL	$32.1 - $40.4 $6,420 - $8,080	-200 Reduced 0.95%	20,900 $704,000
Q3 2019 Nov 12, 2019	BUY	$25.38 - $34.89 $535,518 - $736,179	21,100 New	21,100 $692,000

528

119M

308K

191K

Ticker NTRA
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 96,957,400
Market Cap $16.3B
Description
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify sing...

Get notified when there are updates to the investment portfolio of Alpha Crest Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Alpha Crest Capital Management LLC with notifications on news.